This story is part two in a two-part series looking at thepsychedelics drug development landscape. Part one, which looks at investors' interested in psychedelics,is available here.
Psychedelic drugs are coming out of the jungle and creeping closer to the market, but developers will have to overcome a kitchen sink of regulatory issuesor, maybe more accurately, a living room couch?
Unlike modern pharmaceuticals, such as antidepressant pills or cancer-fighting infusions, the medicinesusedin psychedelics-assisted therapy arenot standalone treatments. Instead, these drugs help a patient reset their brain as they work with a psychotherapist to overcome ailments such as depression and addiction.
The FDA was unsure what to do with the therapy part of it. Do they look at the therapy training program? What is the label going to say? How much do you put in the REMS [Risk Evaluation and Mitigation Strategy] and how much do you put in the label? said Amy Emerson, CEO of MAPS Public Benefit Corporation, a subsidiary set up by the nonprofit Multidisciplinary Association for Psychedelic Studies to develop and commercialize its MDMA-assisted treatment for post-traumatic stress disorder (PTSD).
RELATED: Investors are tripping on psychedelics startups despite a murky path to commercial success
Psychedelicstreatment developers also mustovercomeintellectual property challenges, because thesedrugs are in the public domain or have been used by Indigenous peoples for millennia. They have to figure outhow to open up access to all who need treatment. And they may need to create new business modelsto develop these treatments, not only to help patients and turn a profit but also to do it ethically.
Numerous studies have shown the promise of psychedelics, such as LSD and psilocybin, but research in the field has been hindered by federallaw. The Controlled Substances Act of 1970 classified psychedelics as Schedule I drugs with no currently accepted medical use.
But the tide is turning, thanks in part to the shortcomings of traditional mental health care.Current treatments dont always work well, and they carry side effects such as an increase in alcohol cravings or an increased risk of suicide.
Research and investor interest in psychedelics-based treatment has rebounded in the last decade. Privately funded research centers have popped up at prestigious institutions like Johns Hopkins University and the University of California, Berkeley.
We have very blunt tools that are mostly focused on symptom management rather than trying to help people with their own resiliency and internal ability to make change and potentially overcome the challenges they are having in life, said Evan Wood, M.D., Ph.D., chief medical officer at Numinus, which has partnered with MAPS and Syreon on clinical trials of MDMA- and psilocybin-based therapy, respectively.
The hope is that psychedelics added to talk therapy can achieve what previous approaches haven't, especially as the COVID-19 pandemic has exacerbated mental health problems and highlighted the need for better options,said Jeeshan Chowdhury, M.D., Ph.D., CEO of Journey Colab, a biotech working on a synthetic form of mescaline, a hallucinogenic compound found in some species of cactus, to treat alcohol use disorder.
For MAPS, the stigma around psychedelics did the nonprofit no favors as it tried to get human trials off the ground in the 1990s.
RELATED:Journey Colab bags $3M from 'moonshot' fund to push new development model for psychedelic treatments
Because of a wealth of research into the potential harms of MDMA, the nonprofit didnt need to run a phase 1 study to figure out the best dose of the drug or its side effects.
The nonprofit started itsfirst phase 2 trial in 2004, nine years after it completed the required preclinical studies in 1995.
We had a hard time getting the first study approved because politics were being put in front of the science, Emerson said. Another barrier was moneyMAPS is funded by philanthropy, rather than deep-pocketed venture capitalists like many a psychedelics-focused biotech today. Instead of going full speed ahead on multiple phase 2 trials, MAPS had to carry them out slowly and sequentially, Emerson said.
The nonprofit moved into phase 3 in 2018 and is now recruiting patients for a second phase 3 trial. An FDA decision is anticipatedin 2023.
Though psychedelics research has certain requirements that other drug R&D doesnt, such as secure drug storage and monitoring patients overnight, Emerson views MAPS work as no different from other treatments that are among the first of their kind.
MAPS therapy harnesses MDMA, also known as ecstasy or molly, which was first synthesized by German pharma Merck KGaA in 1912. But other psychedelics-assisted therapies are based on compounds such as psilocybin, mescaline and N,N-dimethyltryptamine, which are found in nature and have been used by Indigenous populations for millennia.
Thats why Chowdhury of Journey Colab thinks of the companys work as translating therapies from a traditional setting to a clinical setting rather than simply drug development.
Some patients may have the means to travel to Indigenous communities to benefit from such treatments, but there are some issues there in terms of sustainability, extractive models and impact on those communities, Chowdhury said.
Some of the plant sources for these medicines are endangered, for example, while history is rife with examples of colonizers exploiting Indigenous peoples, their expertise and their lands.
We need to meet patients and families who suffer from alcohol use disorder where they are We need to bring these therapies to people in their homesnot everyone can or should go to the jungle to experience these therapies, Chowdhury added.
RELATED: From 'party drug' to PTSD treatment: Atai launches EmpathBio to develop MDMA-based therapy
Translating these therapies into a modern healthcare context includes developing synthetic versions and creating methods to deliver reliable, consistent and measurable doses to patients.
For some traditional psychedelic therapies, the 'method of administration is smoking, which is not appropriate for a clinical setting, Chowdhury said. A patient in the clinic versus in a ceremony is going to receive a different type of therapy.
These inventions could address the issue of intellectual property, where companies would patent delivery methods and treatment protocols rather than the psychedelics themselves, some of which are in the public domain and cannot be patented. Johnson & Johnson did just that with thehallucinogenicparty drug ketamine by creating a new formulation called esketamine,which was approved in 2019 as thenasal spray antidepressant Spravato.
Atai Life Sciences is working on shorter-acting psychedelics, which could lessen treatment time for patients and potentiallydeliver the benefits of psychedelics without their hallucinogenic effects.
Still, psychedelics developers remainvulnerable to competitors that could undercut them with cheaper versions.
Thats a concern for Compass Pathways, a biotech working on psilocybin-based therapy for treatment-resistant depression. The company noted competition as a risk in a recent securities filing,not just from biotech and pharma companies but also from nonprofits including the Wisconsin-based Usona Institute, which is researching psilocybin-based therapy for major depressive disorder.
RELATED: Compass plans IPO to take 'magic mushroom' drug to phase 3
To encourage psychedelics R&D, Numinus Wood thinks this class of therapies shouldnt be lumped in with modern pharmaceuticals and instead needs its own regulatory pathway.
This is not a pharmaceutical druga cancer drug, chemotherapy drug or new heart disease drugbut a naturally occurring molecule people have been using for hundreds if not thousands of years, Wood said. There probably needs to be a different regulatory regime for it.
MAPS tried to model its MDMA-assisted psychotherapy after traditional regulatory processes for other pharmaceutical drug approvals.
I wanted to make it look exactly how the FDA or any regulator would expect any other study and drug development program to look, said Emerson, who started out with MAPS as a pro bono consultant in 2003 and became the CEO of its Public Benefit Corporation in 2014.
Some players believe the field needs a new business model to develop and market the therapies. Others think current models can be tweaked, seeing as companies like J&J, GW Pharma and Jazz Pharma have brought versions of Schedule I drugs to market as new medicines for depression, epilepsy and narcolepsy.
Srinivas Rao, M.D., Ph.D., chief scientific officer of psychedelics treatment maker Atai, said in the case of Spravato,patients can self-administer the drugbut have to do sounder the supervision of a healthcare provider in a certified Spravato treatment center over several weeks.
RELATED: Jazz leaps into epilepsy with $7.2B buyout of cannabinoid drugmaker GW Pharma
Was that a markedly different business model? Id argue no, Rao said. "If we can bring it down to make [dosing] much less frequent, well be in pretty good shape.
But Emerson and Chowdhury think this type of treatment requires a bigger change.
We cant just take existing company structures and plug them into psychedelicsthe opportunity with this class of compounds is it forces us to think about different structures, different ways of approaching mental health, Chowdhury said.
For MAPS, a nonprofit dedicated to research, that meant setting up a public benefit corporation rather than a traditional for-profit structure. This allowed them price the drug to maximize patient access while also funding future research.
Journey is treading somewhere between nonprofit and for-profit by putting10% of its founding equity into a trust to share profits with employees, the therapists and caregivers who will administer the treatments, and the Indigenous communities to which the companys medicines trace their roots.
As MAPS PTSD treatment and other psychedelics-based therapies inch closer to regulatory review, the next big question will be how to translate treatments from a tightly controlled clinical trial environment to the real world.
The setting [of therapy] is very important. This is something we have guidelines around and we would have guidelines post-approval as well, Emerson said. It should be comfortable, more like a living room setting than a hospital room.
That includes music, eye shades and a comfortable couch, but the rooms could look different depending on who is providing treatment, ranging from a community-based private practice to clinics at an institution, she said.
MAPS is gaining experience in the real world through an Expanded Access Program, which is approved to treat 50 people.
For now, the MDMA-based treatment will always be given in a clinic under the eye of a therapist. But looking down the roadand if the data support thispatients may be able to take the treatment at home after a certain number of sessions in the clinic, or a therapist may administer treatment in a patients home. Rao of Atai envisions a general practitioner offering these treatments in their offices but acknowledged this would be a long way off.
We have to be negotiating really hard with payers to not only cover the drug but to have new codes to cover the therapy, Emerson said. Therapy is more expensive than the drug. Therapy is not something we get to set the price forwe cant do that, it doesnt belong to us.
But companies dont need to start from scratch: They can build on existing structures, like the 16,000 rehabilitation centers in the U.S., the millions of people already going to therapy each week, and insurance codes and reimbursement models to make this work for patients, Chowdhury said.
There are questions about how were going to pay for this, build all this, Chowdhury said. Already, we are paying for it, especially in addictions. The amount we spend on frustratingly unsuccessful therapies is enormous."
See original here:
Psychedelics are getting closer to approval, but the market may not be ready - FierceBiotech
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]